本帖最后由 老马 于 2013-3-13 13:43 编辑 9 B8 v0 W. B& ~9 V4 I
, v& }$ E6 C& l4 z' y4 h, M7 r健择（吉西他滨）+顺铂+阿瓦斯汀8 f% R; q' s3 ~: B
Gemzar +Cisplatin + Avastin6 R1 W' n; o. K, K- y! O7 D3 O* X
http://annonc.oxfordjournals.org/content/21/9/1804.full
" ~1 a; a3 I1 r8 B3 N7 j) JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
1 E' D* R% Z. \6 q, K% i4 O: W& x- oPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( K2 C$ A( P3 x6 ~% O+ m- g0 R0 GResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
6 }; q1 f3 p$ `. Y0 d+ L- G( A( A$ u
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 371)
5 A" K8 R9 c I( n/ G: m华为网盘附件：5 Y: S/ S) {* n9 s
【华为网盘】ava.JPG
( O1 t3 a5 H% |7 @ |
显身卡
